David Baram is the founder of Emendo Biotherapeutics. Latest round: Series B. Backed by AnGes, OrbiMed Advisors, OrbiMed Israel Partners.
David Baram is the co-founder and CEO of Emendo Biotherapeutics. He has a PhD from the Weizmann Institute of Science in structural biology and a background in protein engineering. Baram has an entrepreneurial spirit, having founded his first company before completing his PhD, and Emendo Biotherapeutics is his fourth venture.
Full founder directory · Investor directory · Company funding database · Fundraising library